Gain-of-Function Variants in Lipid Genes Enhance Biological Insight and Point Toward Therapeutic Opportunities.
作者信息
Stankov Sylvia, Vitali Cecilia, Rader Daniel J
机构信息
Division of Translational Medicine and Therapeutics, Department of Medicine (S.S., C.V., D.J.R.), Perelman School of Medicine, University of Pennsylvania, Philadelphia.
Department of Genetics (D.J.R.), Perelman School of Medicine, University of Pennsylvania, Philadelphia.
出版信息
Circulation. 2022 Sep 6;146(10):740-742. doi: 10.1161/CIRCULATIONAHA.122.061233.
Abstract
摘要
相似文献
1
Gain-of-Function Variants in Lipid Genes Enhance Biological Insight and Point Toward Therapeutic Opportunities.脂质基因功能获得性变异增强生物学认知并指向治疗机会。
Circulation. 2022 Sep 6;146(10):740-742. doi: 10.1161/CIRCULATIONAHA.122.061233.
2
Identification of a Gain-of-Function Variant as a Novel Cause of Familial Combined Hypocholesterolemia.鉴定一种功能获得性变异为家族性混合型高脂血症的新病因。
Circulation. 2022 Sep 6;146(10):724-739. doi: 10.1161/CIRCULATIONAHA.121.057978. Epub 2022 Jul 28.
3
Translational and Therapeutic Approaches to the Understanding and Treatment of Dyslipidemia.血脂异常的理解与治疗的转化及治疗方法
Arterioscler Thromb Vasc Biol. 2016 Jul;36(7):e56-61. doi: 10.1161/ATVBAHA.116.307808.
4
Mixed dyslipidemia among patients using lipid-lowering therapy in French general practice: an observational study.法国全科医疗中接受降脂治疗患者的混合性血脂异常：一项观察性研究。
Clin Ther. 2007 Aug;29(8):1671-81. doi: 10.1016/j.clinthera.2007.08.003.
5
Lipoprotein metabolism in patients with type 1 diabetes under intensive insulin treatment.1 型糖尿病患者强化胰岛素治疗中的脂蛋白代谢。
Lipids Health Dis. 2013 Feb 11;12:15. doi: 10.1186/1476-511X-12-15.
6
Pitavastatin: novel effects on lipid parameters.匹伐他汀：对血脂参数的新作用。
Atheroscler Suppl. 2011 Nov;12(3):277-84. doi: 10.1016/S1567-5688(11)70887-X.
7
Dietary Fat Intake Modifies the Effect of a Common Variant in the LIPC Gene on Changes in Serum Lipid Concentrations during a Long-Term Weight-Loss Intervention Trial.在一项长期减肥干预试验中，膳食脂肪摄入量改变了LIPC基因中一个常见变异对血清脂质浓度变化的影响。
J Nutr. 2015 Jun;145(6):1289-94. doi: 10.3945/jn.115.212514. Epub 2015 Apr 29.
8
Molecule of the Month. TREDAPTIVE (nicotinic acid/laropiprant): a new lipid-modifying therapy for the treatment of LDL-C, HDL-C and triglycerides.
Curr Top Med Chem. 2008;8(14):1310. doi: 10.2174/156802608785849003.
9
Persistent lipid abnormalities in statin-treated patients and predictors of LDL-cholesterol goal achievement in clinical practice in Europe and Canada.在欧洲和加拿大的临床实践中，他汀类药物治疗患者的持续性脂质异常及 LDL-胆固醇目标达标率的预测因子。
Eur J Prev Cardiol. 2012 Apr;19(2):221-30. doi: 10.1177/1741826711400545. Epub 2011 Mar 10.
10
Cardiovascular disease and dyslipidemia: beyond LDL.心血管疾病与血脂异常：不止于 LDL。
Curr Pharm Des. 2011;17(9):861-70. doi: 10.2174/138161211795428858.
引用本文的文献
1
A Comprehensive Review of the Latest Approaches to Managing Hypercholesterolemia: A Comparative Analysis of Conventional and Novel Treatments: Part II.高胆固醇血症管理最新方法的全面综述：传统治疗与新型治疗的比较分析：第二部分
Pharmaceuticals (Basel). 2025 Aug 1;18(8):1150. doi: 10.3390/ph18081150.
本文引用的文献
1
Heart Disease and Stroke Statistics-2022 Update: A Report From the American Heart Association.《心脏病与卒中统计-2022 更新：美国心脏协会报告》。
Circulation. 2022 Feb 22;145(8):e153-e639. doi: 10.1161/CIR.0000000000001052. Epub 2022 Jan 26.
2
Evinacumab for Homozygous Familial Hypercholesterolemia.依洛尤单抗治疗纯合子家族性高胆固醇血症。
N Engl J Med. 2020 Aug 20;383(8):711-720. doi: 10.1056/NEJMoa2004215.
3
LDL-Cholesterol Reduction by ANGPTL3 Inhibition in Mice Is Dependent on Endothelial Lipase.小鼠中通过抑制血管生成素样蛋白3降低低密度脂蛋白胆固醇依赖于内皮脂肪酶。
Circ Res. 2020 Sep 25;127(8):1112-1114. doi: 10.1161/CIRCRESAHA.120.317128. Epub 2020 Aug 17.
4
PCSK9 inhibitors: clinical evidence and implementation.PCSK9 抑制剂：临床证据与应用。
Nat Rev Cardiol. 2019 Mar;16(3):155-165. doi: 10.1038/s41569-018-0107-8.
5
Genome-wide association study identifies a missense variant at APOA5 for coronary artery disease in Multi-Ethnic Cohorts from Southeast Asia.全基因组关联研究鉴定出载脂蛋白 A5 中的错义变异与东南亚多民族队列的冠心病相关。
Sci Rep. 2017 Dec 20;7(1):17921. doi: 10.1038/s41598-017-18214-z.
6
Hemophilia B Gene Therapy with a High-Specific-Activity Factor IX Variant.采用高特异性活性因子IX变体的B型血友病基因疗法。
N Engl J Med. 2017 Dec 7;377(23):2215-2227. doi: 10.1056/NEJMoa1708538.
7
The apolipoprotein C-III (Gln38Lys) variant associated with human hypertriglyceridemia is a gain-of-function mutation.载脂蛋白 C-III (Gln38Lys) 变异与人类高甘油三酯血症相关，是一种获得性功能突变。
J Lipid Res. 2017 Nov;58(11):2188-2196. doi: 10.1194/jlr.M077313. Epub 2017 Sep 8.
8
A human APOC3 missense variant and monoclonal antibody accelerate apoC-III clearance and lower triglyceride-rich lipoprotein levels.一种人类载脂蛋白C3错义变体和单克隆抗体可加速载脂蛋白C-III清除并降低富含甘油三酯的脂蛋白水平。
Nat Med. 2017 Sep;23(9):1086-1094. doi: 10.1038/nm.4390. Epub 2017 Aug 21.
9
Emerging risk biomarkers in cardiovascular diseases and disorders.心血管疾病和病症中新出现的风险生物标志物。
J Lipids. 2015;2015:971453. doi: 10.1155/2015/971453. Epub 2015 Apr 8.
10
Alipogene tiparvovec: a review of its use in adults with familial lipoprotein lipase deficiency.阿利泊基因 tiparvovec：用于治疗家族性脂蛋白脂肪酶缺乏症成人患者的综述。
Drugs. 2015 Feb;75(2):175-82. doi: 10.1007/s40265-014-0339-9.
Zotero 插件